Actively Recruiting
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Led by Dizal Pharmaceuticals · Updated on 2026-04-17
165
Participants Needed
12
Research Sites
189 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.
CONDITIONS
Official Title
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Adult 18 years of age or older
- ECOG performance status score 2 or less
- Life expectancy of at least 12 weeks
- Histopathologically confirmed diagnosis of peripheral T-cell lymphoma
- Presence of measurable disease
- Adequate bone marrow function and vital organ reserve
- Ability to comply with study requirements and complete procedures
- Use of adequate contraception during trial participation
You will not qualify if you...
- Unresolved drug-related adverse events greater than Grade 1
- Lymphoma involving the central nervous system
- Failure to complete required washout period for other anti-tumor therapies
- Corticosteroid use not meeting protocol requirements
- Recent or planned major surgery or trauma within a short period
- Vaccination with live vaccine within a short period
- Inability to discontinue prohibited medications
- Need for immunosuppressive agents or biologics due to underlying disease
- Presence of active infection
- Significant cardiovascular disease
- Gastrointestinal disease affecting drug intake or absorption
- History of other malignancies
- Known allergy to the study drug
- Other severe or uncontrolled systemic diseases
- Personnel with conflict of interest (site staff, sponsor employees)
- Pregnant or breastfeeding women
- Inability to comply with protocol requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Not Yet Recruiting
2
Fujian Cancer Hospital
Fuzhou, Fujian, China
Not Yet Recruiting
3
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China
Not Yet Recruiting
4
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Not Yet Recruiting
5
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Not Yet Recruiting
6
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Not Yet Recruiting
7
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Not Yet Recruiting
8
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Not Yet Recruiting
9
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Not Yet Recruiting
10
Fudan University Shanghai Cancer Center
Shanghai, China
Actively Recruiting
11
Shanxi Provincial Cancer Hospital
Taiyuan, China
Not Yet Recruiting
12
Henan Cancer Hospital
Zhengzhou, China
Not Yet Recruiting
Research Team
J
Jingrun Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here